Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample
Adam Winstock, Michael T. Lynskey, Rohan Borschmann, et al.
Journal of Psychopharmacology (2015) Vol. 29, Iss. 6, pp. 698-703
Closed Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment
Robert J. Tait, David Caldicott, David Mountain, et al.
Clinical Toxicology (2015) Vol. 54, Iss. 1, pp. 1-13
Open Access | Times Cited: 354
Traditional marijuana, high‐potency cannabis and synthetic cannabinoids: increasing risk for psychosis
Robin M. Murray, Harriet Quigley, Diego Quattrone, et al.
World Psychiatry (2016) Vol. 15, Iss. 3, pp. 195-204
Open Access | Times Cited: 250
New psychoactive substances: a review and updates
Abu Shafi, Alex J. Berry, Harry Sumnall, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 242
Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues
Samuel D. Banister, Mitchell Longworth, Richard C. Kevin, et al.
ACS Chemical Neuroscience (2016) Vol. 7, Iss. 9, pp. 1241-1254
Closed Access | Times Cited: 232
Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay
Annelies Cannaert, Jolien Storme, Florian Franz, et al.
Analytical Chemistry (2016) Vol. 88, Iss. 23, pp. 11476-11485
Open Access | Times Cited: 211
Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health
Aviv Weinstein, Paola Rosca, Liana Fattore, et al.
Frontiers in Psychiatry (2017) Vol. 8
Open Access | Times Cited: 181
Cannabis-associated psychosis: Neural substrate and clinical impact
Robin M. Murray, Amir Englund, Anissa Abi‐Dargham, et al.
Neuropharmacology (2017) Vol. 124, pp. 89-104
Closed Access | Times Cited: 177
Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting
Joseph J. Palamar, Sílvia S. Martins, Mark K. Su, et al.
Drug and Alcohol Dependence (2015) Vol. 156, pp. 112-119
Open Access | Times Cited: 162
Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective
Koby Cohen, Aviv Weinstein
Frontiers in Public Health (2018) Vol. 6
Open Access | Times Cited: 154
Moving on From Representativeness: Testing the Utility of the Global Drug Survey
Monica J. Barratt, Jason Ferris, Renee Zahnow, et al.
Substance Abuse Research and Treatment (2017) Vol. 11
Open Access | Times Cited: 111
Emerging drugs of abuse: current perspectives on synthetic cannabinoids
Danièle Debruyne, Reynald Le Boisselier
Substance Abuse and Rehabilitation (2015), pp. 113-113
Open Access | Times Cited: 106
Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data
Katherine I. Morley, Jason Ferris, Adam Winstock, et al.
Pain (2017) Vol. 158, Iss. 6, pp. 1138-1144
Open Access | Times Cited: 89
Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure
L‐S Camilla d'Angelo, George Savulich, Barbara J. Sahakian
British Journal of Pharmacology (2017) Vol. 174, Iss. 19, pp. 3257-3267
Open Access | Times Cited: 83
Novel psychoactive substance use by US adolescents: Characteristics associated with use of synthetic cannabinoids and synthetic cathinones
Megan E. Patrick, Patrick M. O’Malley, Deborah D. Kloska, et al.
Drug and Alcohol Review (2015) Vol. 35, Iss. 5, pp. 586-590
Open Access | Times Cited: 80
User characteristics and effect profile of Butane Hash Oil: An extremely high-potency cannabis concentrate
Gary Chan, Wayne Hall, Tom P. Freeman, et al.
Drug and Alcohol Dependence (2017) Vol. 178, pp. 32-38
Open Access | Times Cited: 79
Cannabinoids: from pot to lab
Esther Papaseit, Clara Pérez‐Mañá, Ana Pilar Pérez-Acevedo, et al.
International Journal of Medical Sciences (2018) Vol. 15, Iss. 12, pp. 1286-1295
Open Access | Times Cited: 71
Application of an activity‐based receptor bioassay to investigate the in vitro activity of selected indole‐ and indazole‐3‐carboxamide‐based synthetic cannabinoids at CB1 and CB2 receptors
Carolina Noble, Annelies Cannaert, Kristían Línnet, et al.
Drug Testing and Analysis (2018) Vol. 11, Iss. 3, pp. 501-511
Closed Access | Times Cited: 71
Adverse Effects, Health Service Engagement, and Service Satisfaction Among Anabolic Androgenic Steroid Users
Renee Zahnow, Jim McVeigh, Jason Ferris, et al.
Contemporary Drug Problems (2017) Vol. 44, Iss. 1, pp. 69-83
Open Access | Times Cited: 64
Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA
David B. Finlay, Jamie J. Manning, Mikkel Søes Ibsen, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 10, pp. 4350-4360
Open Access | Times Cited: 57
Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis
Tabea Schoeler, Jason Ferris, Adam Winstock
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 31
Synthetic cannabinoid induced acute respiratory depression: Case series and literature review
Mark Henry Alon, M. Olibrice Saint-Fleur
Respiratory Medicine Case Reports (2017) Vol. 22, pp. 137-141
Open Access | Times Cited: 61
Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015
Rachelle Abouchedid, Simon Hudson, Natalie Thurtle, et al.
Clinical Toxicology (2017) Vol. 55, Iss. 5, pp. 338-345
Open Access | Times Cited: 56
The Pharmacologic and Clinical Effects of Illicit Synthetic Cannabinoids
C Michael White
The Journal of Clinical Pharmacology (2016) Vol. 57, Iss. 3, pp. 297-304
Open Access | Times Cited: 54
Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset
Giovanni Martinotti, Rita Santacroce, Duccio Papanti, et al.
CNS & Neurological Disorders - Drug Targets (2017) Vol. 16, Iss. 5
Open Access | Times Cited: 54
International trends in spice use: Prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids
George Loeffler, Eileen Delaney, Michael Hann
Brain Research Bulletin (2016) Vol. 126, pp. 8-28
Closed Access | Times Cited: 52
Page 1 - Next Page

Scroll to top